Selected research
Industry Research
Antidiabetic Drug Industry Research Report 2026
Market perspective
The global Antidiabetic Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antidiabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antidiabetic Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antidiabetic Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antidiabetic Drug include Takeda, Eli Lilly, Pfizer, Wockhardt, Tonghua Dongbao, Sanofi-Aventis, Oramed, Novo Nordisk and Halozyme Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antidiabetic Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antidiabetic Drug Market by Company
Takeda
Eli Lilly
Pfizer
Wockhardt
Tonghua Dongbao
Sanofi-Aventis
Oramed
Novo Nordisk
Halozyme Therapeutics
Bristol-Myers Squibb
Boehringer Ingelheim
Biocon
Antidiabetic Drug Segment by Type
Dpp-4 Inhibitors
Glp-1 Agonist
Alpha-Glucosidase Inhibitors
Sglt–2
Thiazolodinediones
Meglitinides
Biguanides, Sulphonylureas
Antidiabetic Drug Segment by Application
Type I Diabetes
Type II Diabetes
Antidiabetic Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antidiabetic Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antidiabetic Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antidiabetic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Dpp-4 Inhibitors
- Glp-1 Agonist
- Alpha-Glucosidase Inhibitors
- Sglt–2
- Thiazolodinediones
- Meglitinides
- Biguanides, Sulphonylureas
Applications
- Type I Diabetes
- Type II Diabetes
Companies covered
- Takeda
- Eli Lilly
- Pfizer
- Wockhardt
- Tonghua Dongbao
- Sanofi-Aventis
- Oramed
- Novo Nordisk
- Halozyme Therapeutics
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Biocon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antidiabetic Drug Market Size (2021-2032)
- 2.2.2 Global Antidiabetic Drug Sales (2021-2032)
- 2.2.3 Global Antidiabetic Drug Market Average Price (2021-2032)
- 2.3 Antidiabetic Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Dpp-4 Inhibitors
- 2.3.3 Glp-1 Agonist
- 2.3.4 Alpha-Glucosidase Inhibitors
- 2.3.5 Sglt–2
- 2.3.6 Thiazolodinediones
- 2.3.7 Meglitinides
- 2.3.8 Biguanides, Sulphonylureas
- 2.4 Antidiabetic Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Type I Diabetes
- 2.4.3 Type II Diabetes
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antidiabetic Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antidiabetic Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antidiabetic Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Antidiabetic Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Antidiabetic Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antidiabetic Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antidiabetic Drug, Product Type & Application
- 3.8 Global Manufacturers of Antidiabetic Drug, Established Date
- 3.9 Global Antidiabetic Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Antidiabetic Drug Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Eli Lilly
- 4.2.1 Eli Lilly Company Information
- 4.2.2 Eli Lilly Business Overview
- 4.2.3 Eli Lilly Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eli Lilly Antidiabetic Drug Product Portfolio
- 4.2.5 Eli Lilly Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Antidiabetic Drug Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Wockhardt
- 4.4.1 Wockhardt Company Information
- 4.4.2 Wockhardt Business Overview
- 4.4.3 Wockhardt Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Wockhardt Antidiabetic Drug Product Portfolio
- 4.4.5 Wockhardt Recent Developments
- 4.5 Tonghua Dongbao
- 4.5.1 Tonghua Dongbao Company Information
- 4.5.2 Tonghua Dongbao Business Overview
- 4.5.3 Tonghua Dongbao Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Tonghua Dongbao Antidiabetic Drug Product Portfolio
- 4.5.5 Tonghua Dongbao Recent Developments
- 4.6 Sanofi-Aventis
- 4.6.1 Sanofi-Aventis Company Information
- 4.6.2 Sanofi-Aventis Business Overview
- 4.6.3 Sanofi-Aventis Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sanofi-Aventis Antidiabetic Drug Product Portfolio
- 4.6.5 Sanofi-Aventis Recent Developments
- 4.7 Oramed
- 4.7.1 Oramed Company Information
- 4.7.2 Oramed Business Overview
- 4.7.3 Oramed Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Oramed Antidiabetic Drug Product Portfolio
- 4.7.5 Oramed Recent Developments
- 4.8 Novo Nordisk
- 4.8.1 Novo Nordisk Company Information
- 4.8.2 Novo Nordisk Business Overview
- 4.8.3 Novo Nordisk Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novo Nordisk Antidiabetic Drug Product Portfolio
- 4.8.5 Novo Nordisk Recent Developments
- 4.9 Halozyme Therapeutics
- 4.9.1 Halozyme Therapeutics Company Information
- 4.9.2 Halozyme Therapeutics Business Overview
- 4.9.3 Halozyme Therapeutics Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Halozyme Therapeutics Antidiabetic Drug Product Portfolio
- 4.9.5 Halozyme Therapeutics Recent Developments
- 4.10 Bristol-Myers Squibb
- 4.10.1 Bristol-Myers Squibb Company Information
- 4.10.2 Bristol-Myers Squibb Business Overview
- 4.10.3 Bristol-Myers Squibb Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bristol-Myers Squibb Antidiabetic Drug Product Portfolio
- 4.10.5 Bristol-Myers Squibb Recent Developments
- 4.11 Boehringer Ingelheim
- 4.11.1 Boehringer Ingelheim Company Information
- 4.11.2 Boehringer Ingelheim Business Overview
- 4.11.3 Boehringer Ingelheim Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Boehringer Ingelheim Antidiabetic Drug Product Portfolio
- 4.11.5 Boehringer Ingelheim Recent Developments
- 4.12 Biocon
- 4.12.1 Biocon Company Information
- 4.12.2 Biocon Business Overview
- 4.12.3 Biocon Antidiabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Biocon Antidiabetic Drug Product Portfolio
- 4.12.5 Biocon Recent Developments
5 Global Antidiabetic Drug Market Scenario by Region
- 5.1 Global Antidiabetic Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antidiabetic Drug Sales by Region: 2021-2032
- 5.2.1 Global Antidiabetic Drug Sales by Region: 2021-2026
- 5.2.2 Global Antidiabetic Drug Sales by Region: 2027-2032
- 5.3 Global Antidiabetic Drug Revenue by Region: 2021-2032
- 5.3.1 Global Antidiabetic Drug Revenue by Region: 2021-2026
- 5.3.2 Global Antidiabetic Drug Revenue by Region: 2027-2032
- 5.4 North America Antidiabetic Drug Market Facts & Figures by Country
- 5.4.1 North America Antidiabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antidiabetic Drug Sales by Country (2021-2032)
- 5.4.3 North America Antidiabetic Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antidiabetic Drug Market Facts & Figures by Country
- 5.5.1 Europe Antidiabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antidiabetic Drug Sales by Country (2021-2032)
- 5.5.3 Europe Antidiabetic Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Antidiabetic Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antidiabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antidiabetic Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antidiabetic Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antidiabetic Drug Market Facts & Figures by Country
- 5.7.1 South America Antidiabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antidiabetic Drug Sales by Country (2021-2032)
- 5.7.3 South America Antidiabetic Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Antidiabetic Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antidiabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antidiabetic Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antidiabetic Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antidiabetic Drug Sales by Type (2021-2032)
- 6.1.1 Global Antidiabetic Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antidiabetic Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Antidiabetic Drug Revenue by Type (2021-2032)
- 6.2.1 Global Antidiabetic Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antidiabetic Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Antidiabetic Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antidiabetic Drug Sales by Application (2021-2032)
- 7.1.1 Global Antidiabetic Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antidiabetic Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Antidiabetic Drug Revenue by Application (2021-2032)
- 7.2.1 Global Antidiabetic Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antidiabetic Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Antidiabetic Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antidiabetic Drug Value Chain Analysis
- 8.1.1 Antidiabetic Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antidiabetic Drug Production Mode & Process
- 8.2 Antidiabetic Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antidiabetic Drug Distributors
- 8.2.3 Antidiabetic Drug Customers
9 Global Antidiabetic Drug Analyzing Market Dynamics
- 9.1 Antidiabetic Drug Industry Trends
- 9.2 Antidiabetic Drug Industry Drivers
- 9.3 Antidiabetic Drug Industry Opportunities and Challenges
- 9.4 Antidiabetic Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst